

EARLY DIAGNOSIS, THE KEY TO REDUCING THE GLOBAL BURDEN OF CANCER

NAVEED SHUJA¹

¹Dean, Professor Department of Bio-Chemistry, Lahore Medical & Dental College, Lahore
Correspondence to: Naveed Shuja, Email: rananaveedshuja@gmail.com, Cell: +92334205687

This editorial may be cited as: Shuja N: Early Diagnosis, The Key To Reducing The Global Burden Of Cancer. Pak Med & Allied, 2025; 01(2): 1-3.

Received: 10-02-2025

Revised: 15-04-2025

Accepted: 15-05-2025

Published: 30-05-2025

© The Author(s) 2025. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International License \(CC BY 4.0\)](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.



Cancer remains one of the leading causes of death worldwide, claiming nearly 10 million lives annually. Its impact is profound not only on individuals and families but also on healthcare systems and economies¹. Despite remarkable advances in treatment, late diagnosis continues to be the single most significant factor contributing to poor outcomes. Early detection offers the best opportunity to reduce mortality, improve survival, and minimize the financial and emotional toll of the disease. If countries are to make meaningful progress against cancer, early diagnosis must become the cornerstone of their national cancer control strategies².

The Power of Early Detection:

The survival rate for most cancers is closely linked to the stage at which the disease is detected. Cancers diagnosed at an early stage before metastasis are far more likely to respond to curative treatment. For example, breast cancer survival exceeds 90% when detected early, compared to less than 30% when diagnosed at an advanced stage. Similar patterns are seen in cervical, colorectal, oral, and lung cancers. Early detection reduces not only mortality but also morbidity. Patients diagnosed early often require less aggressive treatments, have fewer complications, and enjoy a better quality of life. This also means reduced hospital stays, lower healthcare costs, and a more sustainable health system. In many cases, early diagnosis allows for less invasive and more cost-effective interventions^{3,4}.

Global Disparities in Cancer Diagnosis:

A striking feature of the global cancer burden is the inequity between high- and low-income countries. While cancer survival has improved significantly in developed nations due to advanced screening programs and early detection initiatives, many low- and middle-income countries (LMICs) continue to face high mortality rates⁵. The reasons are multifactorial: limited access to screening

services, lack of public awareness, inadequate diagnostic infrastructure, cultural stigma, and late presentation. For instance, more than 70% of cancer cases in sub-Saharan Africa and parts of South Asia are diagnosed at advanced stages, when treatment options are limited and often unaffordable. The same disease that is manageable in one part of the world becomes fatal in another simply because it is detected too late. Bridging this gap is one of the greatest public health challenges of our time⁶.

Public Awareness: The First Step:

Early diagnosis begins in the community, not in the hospital. Many patients delay seeking care because they do not recognize early symptoms, or they underestimate their significance. In some cultures, fear, stigma, or misconceptions about cancer discourage people from seeking medical help. For others, geographic or financial barriers prevent timely access to health services. Public education campaigns can transform this landscape⁷. Raising awareness about common cancer symptoms, the importance of early check-ups, and the availability of screening can lead to earlier presentations and better outcomes. Such campaigns should be culturally sensitive, community-driven, and supported by media, schools, workplaces, and local health workers. Empowering individuals with knowledge is one of the most cost-effective interventions⁸.

The Role of Screening Programs:

While awareness encourages early presentation, screening programs enable early detection in asymptomatic individuals. Screening for breast, cervical, colorectal, and prostate cancers has proven to reduce mortality significantly in countries where such programs are systematically implemented. For example, mammography has been instrumental in reducing breast cancer mortality in high-income countries⁹. Cervical cancer screening through Pap smears and HPV testing has dramatically

lowered incidence and deaths in many regions. Similarly, colonoscopy and fecal occult blood tests are effective in detecting early colorectal cancer or precancerous lesions. However, in many LMICs, these programs are either absent or poorly implemented due to financial constraints, lack of trained personnel, or weak health infrastructure. Adopting low-cost, evidence-based screening strategies that fit local health systems is crucial. For example, visual inspection with acetic acid (VIA) for cervical cancer screening is an effective and inexpensive tool in resource-limited settings¹⁰.

Strengthening Diagnostic Capacity:

Early diagnosis is only meaningful if timely and accurate diagnostic services are available. Unfortunately, many health facilities in low-resource countries lack pathology labs, imaging services, or trained oncologists. This results in diagnostic delays, misdiagnosis, and loss of follow-up. Investing in basic diagnostic infrastructure such as ultrasound, mammography, endoscopy, cytology, and histopathology is a critical step. Equally important is the training of healthcare professionals, including primary care providers, in early cancer detection, referral pathways, and patient counseling. A well-coordinated referral system can ensure that patients reach diagnostic and treatment centers without unnecessary delays¹¹.

Primary Care as the First Line of Defense:

Primary healthcare providers often represent the first point of contact for patients. Strengthening their ability to recognize warning signs of cancer, initiate early investigations, and refer appropriately can greatly reduce diagnostic delays⁹. Integrating cancer awareness and early detection protocols into primary healthcare services also ensures that early diagnosis becomes a routine, accessible part of care rather than a specialized luxury. In rural areas, mobile clinics and telemedicine can help bring diagnostic services closer to underserved populations. This approach can overcome geographic barriers and allow timely consultations with specialists when needed¹².

Technology and Innovation:

Technological innovation offers new opportunities for early cancer detection at scale. Advances in molecular diagnostics, artificial intelligence (AI), and point-of-care testing can improve accuracy and accessibility⁸. AI-driven imaging tools, for example, can assist in detecting breast or lung cancer from X-rays or mammograms with high precision even in settings with limited radiologists. Similarly, liquid biopsies and simple blood-based screening tools are being developed, which could revolutionize early diagnosis by identifying cancer biomarkers non-invasively. For LMICs, such innovations if made affordable and scalable could bypass many infrastructure barriers that currently limit screening and diagnosis⁶.

Policy and Health System Strengthening:

No early diagnosis strategy can succeed without strong political commitment and policy support. Governments must prioritize early cancer detection within national health agendas, allocate sufficient resources, and integrate it into universal health coverage frameworks. National cancer control plans should include organized screening programs, referral systems, and data collection to monitor effectiveness and equity. Partnerships between governments, NGOs, academic institutions, and the private sector can facilitate resource mobilization, capacity building, and innovation. International collaboration is particularly important in knowledge sharing, research, and technology transfer⁷⁻¹⁰.

Economic and Social Benefits:

Investing in early diagnosis is not just a health priority it makes economic sense. Treating advanced cancer is far more expensive than detecting and treating early disease. Early-stage treatment often involves fewer complex procedures, shorter hospital stays, and reduced loss of productivity for patients and caregivers. By shifting resources upstream, health systems can save costs and improve outcomes simultaneously. Moreover, early detection and successful treatment help patients remain active members of their families and communities, reducing the social and economic burden of long-term illness or premature death^{11,12}.

Ethical and Equity Considerations:

Cancer early detection must be accessible to all, not just the privileged few. Equity should guide screening and diagnostic strategies, ensuring that rural populations, women, low-income groups, and marginalized communities are not left behind. Ethical considerations also include ensuring informed consent, confidentiality, and culturally sensitive communication during screening and diagnosis. A people-centered approach that respects patients' rights and dignity builds trust and encourages participation in early detection programs¹⁻⁸.

A Global Call to Action:

The fight against cancer cannot be won by treatment alone. Early diagnosis is the most powerful weapon we have to reduce the global cancer burden. Governments must invest in awareness, screening, diagnostic infrastructure, and primary care systems. Researchers and innovators must focus on affordable technologies suitable for all contexts⁵. Communities must be empowered with knowledge and supported to act early. The path forward requires collaboration, commitment, and vision. By detecting cancer early, we can transform it from a death sentence to a manageable disease, save millions of lives, reduce suffering, and build stronger, more equitable health systems⁷.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209–49. doi:10.3322/caac.21660
2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3). *Lancet*. 2020;391(10125):1023–75. doi:10.1016/S0140-6736(17)33326-3
3. Ward ZJ, Scott AM, Hricak H, Abdel-Wahab M, Paez D, Riviere P, et al. Estimates of the global potential for early cancer diagnosis. *Lancet Glob Health*. 2020;8(6):e729–36. doi:10.1016/S2214-109X(20)30061-6
4. World Health Organization. *Guide to cancer early diagnosis*. Geneva: WHO; 2020. Available from: <https://www.who.int/publications>
5. Horton S, Sullivan R. Early detection of cancer: a global perspective. *Nat Rev Cancer*. 2021;21(9):556–67. doi:10.1038/s41568-021-00363-7
6. Sung H, Hyun N, Jemal A, Kim Y, He J, Naqvi AA, et al. Breast cancer screening, diagnosis, and treatment in low-income settings. *JAMA*. 2022;327(24):2411–23. doi:10.1001/jama.2022.8977
7. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of global burden of cervical cancer in 2020. *Lancet Glob Health*. 2022;10(2):e161–9. doi:10.1016/S2214-109X(21)00467-9
8. Gupta S, McClure TD, Murphy JD, Sanoff HK, Fisher DA. Cost-effectiveness of colorectal cancer screening strategies. *JAMA Netw Open*. 2020;3(11):e2021483. doi:10.1001/jamanetworkopen.2020.21483
9. Basu P, Muwonge R, Taghavi K, Lucas E, Sankaranarayanan R. Visual inspection with acetic acid for cervical cancer screening in low-resource settings. *Int J Cancer*. 2021;149(3):528–38. doi:10.1002/ijc.33561
10. Salama K, Zahid U, Chen H, Kiran T, Sarwar S. Primary care's role in early cancer diagnosis. *Cancer Control*. 2021;28:10732748211018337. doi:10.1177/10732748211018337
11. McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafi H, et al. AI-based detection of breast cancer in mammography. *Nature*. 2020;577(7788):89–94. doi:10.1038/s41586-019-1799-6
12. Siravegna G, Marsoni S, Siena S, Bardelli A. Liquid biopsies for early cancer detection. *Nat Rev Clin Oncol*. 2022;19(6):337–50. doi:10.1038/s41571-022-00614-7

Publisher's Note:

Annals of Pakistan Medical & Allied Professionals (Pak Med & Allied) remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.